A61K 39/025
Enterobacteriales
Official title: {Enterobacteriales, e.g. Enterobacter}
A61K39/025 (Enterobacteriales) appears on 951 US grants and 1,221 published applications in this corpus.
Search patents in A61K- Granted patents
- 951
- Published applications
- 1,221
- Assignees
- 620
- Inventors
- 2,056
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 2 | 0 |
| 1978 | 1 | 0 |
| 1979 | 5 | 0 |
| 1980 | 2 | 0 |
| 1981 | 4 | 0 |
| 1982 | 8 | 0 |
| 1983 | 4 | 0 |
| 1984 | 6 | 0 |
| 1985 | 2 | 0 |
| 1986 | 3 | 0 |
| 1987 | 2 | 0 |
| 1988 | 10 | 0 |
| 1989 | 5 | 0 |
| 1990 | 1 | 0 |
| 1991 | 2 | 0 |
| 1992 | 3 | 0 |
| 1993 | 6 | 0 |
| 1994 | 5 | 0 |
| 1995 | 6 | 0 |
| 1996 | 5 | 0 |
| 1997 | 12 | 0 |
| 1998 | 15 | 0 |
| 1999 | 10 | 0 |
| 2000 | 14 | 0 |
| 2001 | 8 | 3 |
| 2002 | 12 | 29 |
| 2003 | 11 | 24 |
| 2004 | 12 | 32 |
| 2005 | 22 | 29 |
| 2006 | 20 | 26 |
| 2007 | 14 | 31 |
| 2008 | 13 | 35 |
| 2009 | 12 | 35 |
| 2010 | 17 | 54 |
| 2011 | 26 | 64 |
| 2012 | 33 | 45 |
| 2013 | 31 | 50 |
| 2014 | 45 | 56 |
| 2015 | 65 | 73 |
| 2016 | 57 | 80 |
| 2017 | 43 | 61 |
| 2018 | 44 | 53 |
| 2019 | 48 | 54 |
| 2020 | 60 | 54 |
| 2021 | 44 | 65 |
| 2022 | 42 | 56 |
| 2023 | 40 | 57 |
| 2024 | 36 | 65 |
| 2025 | 44 | 53 |
| 2026 | 18 | 37 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Use of E. coli strains expressing high level of α-Gal to modulate immunity and provide protection against infectious diseases in animals29 Sep 2026US 12,745,790 B2Biologicke Centrum AV CR v. v. i.
- Immunomodulatory and oncolytic minicells and methods of use22 Sep 2026US 12,741,010 B2Vaxiion Therapeutics, Inc.
- Klebsiella vaccine and methods of use11 Aug 2026US 12,702,704 B2Cornell University
- Proteins and immunizing compositions containing Klebsiella proteins and methods of use28 Jul 2026US 12,691,167 B2Vaxxinova US, Inc.
- Vaccine21 Jul 2026US 12,685,769 B2Glaxosmithkline Biologicals SA
- Development of carbohydrate-based anti-salmonella vaccines8 Oct 2026US 2026/0306602 A1Board of Trustees of Michigan State University
- A broadly protective prophylactic vaccine against pseudomonas aeruginosa24 Sep 2026US 2026/0284172 A1University of Kansas
- Polynucleotide compositions and uses thereof3 Sep 2026US 2026/0256900 A1Pfizer Inc.
- Use of O-Antigens for Treating Bacterial Infections20 Aug 2026US 2026/0240973 A1Agency for Science, Technology and Research
- Oral vaccine20 Aug 2026US 2026/0240985 A1WestfäLische Wilhelms-UniversitäT MüNster
Most cited
By later US patents
- Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix365US 6,309,669 B1The United States of America as represented by the Secretary of the Army · 2001
- Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres118US 5,417,986 AThe United States of America as represented by the Secretary of the Army · 1995
- Avirulent microbes and uses therefor: Salmonella typhi109US 5,387,744 AWashington University · 1995
- Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli104US 8,758,764 B2J. Craig Venter Institute, Inc. · 2014
- Avirulent microbes and uses therefor: salmonella typhi103US 5,294,441 AWashington University · 1994